Krystal Biotech, Inc.

NASDAQ:KRYS

153.22 (USD) • At close July 30, 2025
Bedrijfsnaam Krystal Biotech, Inc.
Symbool KRYS
Munteenheid USD
Prijs 153.22
Beurswaarde 4,427,858,814
Dividendpercentage 0%
52-weken bereik 122.8 - 212.06
Industrie Biotechnology
Sector Healthcare
CEO Mr. Krish S. Krishnan M.B.A., M.S.
Website https://www.krystalbio.com

An error occurred while fetching data.

Over Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved

Vergelijkbare Aandelen

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.56 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

15.48 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

41.96 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

30.77 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

107.88 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

135.23 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

11.17 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

3.04 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

33.56 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)